Boston Scientific Launches New Implantable Defibrillation Lead in Europe and Asia

by Benzinga Staff
September 24, 2012 7:38 AM | 16 seconds read

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.

Boston Scientific Corporation (NYSE: BSX) has received regulatory approval tomarket the RELIANCE® 4-FRONT™ lead, its next generation implantabledefibrillation lead now available in Europe and Asia.  Defibrillation leadsare insulated wires that connect an implantable cardioverter defibrillator(ICD) or cardiac resynchronization therapy defibrillator to the heart fortreatment of heart failure and sudden cardiac arrest.

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: NewsFDAGlobal

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.